Sources last read
Mounjaro dosage schedule
Mounjaro starts at 2.5 mg once a week. Its maximum dose is 15 mg. The 2.5 mg dose can continue for blood sugar control. Further increases depend on response.
Source for this answer
Source: Read from the Mounjaro label, revision 08/2026
Source: Read from the Mounjaro label, revision 08/2026
Medically reviewed by Jennifer Montecillo, MD · non-practicing medical reviewerReviewed 2026-08-12every number here is sourced
Key dose facts
Key facts
- 2.5 mg once a week
- 2.5 mg can continue; increases depend on blood sugar control
- 15 mg once a week
- Shown step by step below
The Mounjaro dosages, step by step
The label permits 2.5 mg increases after at least 4 weeks on the current dose, only if more blood sugar control is needed. These are optional steps, not an automatic schedule.
| When | Weekly dose | Can you stay here? | What the label notes |
|---|---|---|---|
| Starting dosage | 2.5 mg | Yes | Starting dose; also allowed for ongoing blood sugar control under the August 2026 approval |
| After at least 4 weeks on 2.5 mg | 5 mg | Yes | Only if additional blood sugar control is needed |
| After at least 4 weeks on 5 mg | 7.5 mg | Yes | Only where blood sugar needs more help |
| After at least 4 weeks on 7.5 mg | 10 mg | Yes | The ceiling for patients aged 10 to 17 |
| After at least 4 weeks on 10 mg | 12.5 mg | Yes | Adults only |
| After at least 4 weeks on 12.5 mg | 15 mg | Yes | Maximum for adults |
Which dose do you end up on?
The Mounjaro label names no set of maintenance dosages. It says to move up in 2.5 mg steps, and only where blood sugar needs more help. Each step needs at least 4 weeks on the one before it. The ceiling is 15 mg for adults and 10 mg from age 10. The August 2026 approval allows 2.5 mg for ongoing blood sugar control too.
| Who the label covers | Dose to settle on | Approved |
|---|---|---|
| Adults with type 2 diabetes, alongside diet and exercise, to improve blood sugar control | No named set — the label steps up in 2.5 mg increments while blood sugar needs more help, to a ceiling of 15 mg | 2022-05-13NDA 215866 |
| Children and teenagers aged 10 years and older with type 2 diabetes, alongside diet and exercise. The FDA granted this after a 30-week trial in 99 young patients that Lilly owed as a condition of the original approval | The same step pattern, stopping at 10 mg rather than 15 mg | 2025-12-19NDA 215866/S-039 |
| Adults with type 2 diabetes who are at high risk of cardiovascular death, non-fatal heart attack or non-fatal stroke, to reduce that risk | The label specifies a 2.5 mg weekly start, with further increases only if more blood sugar control is needed | 2026-08-27NDA 215866/S-044 |
15 mg once weekly is the maximum for adults. For pediatric patients aged 10 years and older, the maximum is 10 mg once weekly.
12Label details
Who does the label cover, and who does it not?
Patients aged 10 and older with type 2 diabetes are covered, on the same step pattern, with a ceiling of 10 mg rather than 15 mg. The label says the KwikPen is not meant for young patients to inject themselves, and that nothing has been established below age 10.
The Mounjaro label covers neither weight loss nor sleep apnea. Its trials measured weight change, but that is not what the label approves it for.
What if a week gets missed?
The label says a missed dose can be given within 4 days, which is 96 hours. Past 4 days it says to skip that week and go back to the usual day.
The label allows the weekly day to move as long as two doses stay at least 3 days, or 72 hours, apart.
What does it come in?
The device matters for dosing, because some of these hold one dose and some hold four.
| Device | Strengths | Doses inside |
|---|---|---|
| Single-dose pen | 2.5, 5, 7.5, 10, 12.5 and 15 mg per 0.5 mL | 1 dose |
| Single-dose vial | 2.5, 5, 7.5, 10, 12.5 and 15 mg per 0.5 mL | 1 dose |
| Multi-dose vial | 10 to 60 mg per 2.4 mL, giving 2.5 to 15 mg per 0.6 mL dose | 4 doses |
| Single-patient-use KwikPen | 10 to 60 mg per 2.4 mL, giving 2.5 to 15 mg per dose | 4 doses |
Mounjaro and Zepbound are the same drug. So why are the doses different?
Zepbound is the same drug substance from the same manufacturer, approved for weight and sleep apnea rather than blood sugar, and it names 5, 10 and 15 mg as the doses to settle on.
Both products contain tirzepatide, and both come from Eli Lilly and Company. They were approved under separate applications, NDA 215866 and NDA 217806. Each label sets out its approved uses, dose schedule and instructions for a missed dose.
The highest labeled doses are 15 mg for Mounjaro and 15 mg for Zepbound. Their shared ingredient does not make their dose plans interchangeable.
Both labels print 2.5 and 5 mg. Those are the same amounts of tirzepatide on either label. What changes is where each one sits. 2.5 mg is a dose you can stay on with Mounjaro, and only a step on Zepbound.
How long does it take to reach the 15 mg dose?
The label does not promise one date. It sets the timing for each step in the schedule below.
Mounjaro starts at 2.5 mg and has a 15 mg ceiling. Read the published timing beside each row rather than adding the waits into one calendar estimate.
Nothing in the label says a person has to keep climbing. The maintenance choices are listed separately below.
Whether to move up, stay put or stop is a decision for whoever wrote the prescription.
Can you stay on a low dose of Mounjaro?
The label allows 2.5 mg for ongoing blood sugar control. Higher doses depend on whether more control is needed.
There is no fixed list of maintenance doses. That does not mean everyone has to leave the starting dose.
The label allows an increase only when more blood sugar control is needed, after at least four weeks on the current dose.
The maximum is 15 mg for adults. The dose that suits one person is a decision for their prescriber.
How does the Mounjaro schedule compare with other GLP-1 brands?
Mounjaro tops out at 15 mg once a week. Compare starting and ongoing doses for the 9 brands below.
The table below compares the highest labeled doses, starting doses and ongoing dose choices. Each row comes from that product’s label.
Milligrams do not carry across molecules. 15 mg of tirzepatide is not comparable to 15 mg of anything else. The last column says so on every row where the drug substance differs.
Brands can share a drug but differ in form, approved use or dose schedule. A matching milligram amount does not make products interchangeable.
| Brand | Drug | Starts at | Tops out at | Doses to stay on | Against Mounjaro |
|---|---|---|---|---|---|
| Foundayo | Orforglipron | 0.8 mg daily | 17.2 mg | 5.5 mg can continue; further increases depend on response and tolerability | Different drug — milligrams do not compare |
| Zepbound | Tirzepatide | 2.5 mg weekly | 15 mg | 5, 10 and 15 mg | Same drug, same 15 mg ceiling |
| Mounjaro | Tirzepatide | 2.5 mg weekly | 15 mg | 2.5 mg can continue; increases depend on blood sugar control | This page |
| Rybelsus | Semaglutide | 3 mg daily | 14 mg | 7 and 14 mg | Different drug — milligrams do not compare |
| Wegovy | Semaglutide | 0.25 mg weekly | 7.2 mg | 1.7, 2.4 and 7.2 mg | Different drug — milligrams do not compare |
| Trulicity | Dulaglutide | 0.75 mg weekly | 4.5 mg | 0.75 mg can continue; increases depend on blood sugar control | Different drug — milligrams do not compare |
| Saxenda | Liraglutide | 0.6 mg daily | 3 mg | 2.4 and 3 mg | Different drug — milligrams do not compare |
| Ozempic | Semaglutide | 0.25 mg weekly | 2 mg | 0.5, 1 and 2 mg | Different drug — milligrams do not compare |
| Victoza | Liraglutide | 0.6 mg daily | 1.8 mg | 1.2 and 1.8 mg | Different drug — milligrams do not compare |
Do the side effects change as the dose goes up?
The main label table reports separate results for Mounjaro 5 mg, Mounjaro 10 mg, Mounjaro 15 mg.
A trial group’s assigned dose and each dose increase are different things. The table counts reports over the study, including time spent increasing doses.
These group results cannot tell someone whether a dose change caused their symptoms. Read each result with its trial group and study period.
The Mounjaro side-effect page shows the full table and the group behind each percentage. The schedule here gives the label’s timing for dose changes.
What is the most important information I should know about Mounjaro?
The label’s boxed warning covers thyroid tumors in rodents
Like every drug in this family, Mounjaro opens with a boxed warning drawn from rat studies that found thyroid C-cell tumors. The human risk is unknown. Anyone with medullary thyroid cancer in the family, or with the inherited condition MEN 2, is ruled out by the label.
A boxed warning is the strongest warning the FDA applies. It appears at the top of the label, before the dosing section summarized here.
A lower dose does not remove the boxed warning. The warning is separate from the common side-effect percentages in trial tables.
Do not use Mounjaro if:
The label lists reasons a person must not use Mounjaro. The boxed warning covers some of these; the full label gives the complete list.
The label’s contraindications section lists reasons not to use the drug. The boxed warning alone is not the full list.
The label separately lists 8 serious effects it tells prescribers to watch for. Each one is set out with the label’s own wording on the Mounjaro side-effect page.
The dose schedule comes from the prescribing label. Read the full label for the complete list of reasons not to take it.
What are the possible side effects of Mounjaro?
The most common in the label’s own trial table is nausea, reported by 18% on Mounjaro 15 mg.
That figure comes from one trial group. Its dose, study population and follow-up period matter when reading the percentage.
The trial reports effects for each assigned group over the study. Those totals do not isolate what happened after each dose increase.
The full table, every arm and the placebo column beside it, sits on the Mounjaro side-effect page.
Where to read next
4 pages sit next to this one, and each answers something this page deliberately does not.
- Mounjaro side effects, dose by dose carries the label’s own trial table.
- The tirzepatide dosage chart covers the drug rather than the brand, including the vial and syringe arithmetic no pen needs.
- Storing Mounjaro safely covers the fridge, the room-temperature window and what the label leaves out.
- What Mounjaro costs reads the price off the manufacturer’s own terms rather than the label, including who those terms shut out.
- Mounjaro (tirzepatide) injection — FDA-approved Prescribing Information (DailyMed)retrieved 2026-09-13FDA label
- Drugs@FDA approval history — NDA 215866, Mounjaro (tirzepatide) injectionretrieved 2026-08-12FDA label
- FDA approval letter, NDA 215866 — Mounjaro (tirzepatide) injection, glycemic control in adults with type 2 diabetesretrieved 2026-08-12FDA label
- FDA supplement approval letter, NDA 215866/S-039 — expansion of the Mounjaro type 2 diabetes indication to pediatric patients aged 10 years and older (trial I8F-MC-GPGV)retrieved 2026-08-12FDA label
- FDA supplement approval letter, NDA 215866/S-044 and S-045 — Mounjaro heart-risk reduction and 2.5 mg for ongoing blood sugar controlretrieved 2026-09-13FDA label